Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, single-arm, phase II study Induction osimertinib followed by definitive sequential radiation therapy and/or surgery in unresectable EGFR-mutant stage III NSCLC

Next Previous
Search
Trial Profile

An open-label, single-arm, phase II study Induction osimertinib followed by definitive sequential radiation therapy and/or surgery in unresectable EGFR-mutant stage III NSCLC

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 01 Sep 2023 Results published in the International Journal of Radiation Oncology, Biology, Physics
    • 23 Oct 2022 New trial record
    • 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top